Naz Rahman
Stock Analyst at Maxim Group
(0.29)
# 4,322
Out of 5,043 analysts
35
Total ratings
20%
Success rate
-45.61%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $7.30 | +173.97% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.21 | +216.74% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.38 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $6.55 | +159.54% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $3.47 | +2,061.38% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $35.93 | +94.82% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.14 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $3.76 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.66 | +381.93% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.32 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.81 | +269.78% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $13.20 | +960.61% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $420.17 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.31 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.58 | +132.56% | 1 | Feb 25, 2022 |
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $7.30
Upside: +173.97%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.21
Upside: +216.74%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.38
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $6.55
Upside: +159.54%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $3.47
Upside: +2,061.38%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $35.93
Upside: +94.82%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $3.76
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.66
Upside: +381.93%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.32
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.81
Upside: +269.78%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $13.20
Upside: +960.61%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $420.17
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.31
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.58
Upside: +132.56%